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Abstract
In view of the increasing use of pneumococcal vaccines, especially in the developing world, there is a need for appropriate diagnostics
to understand the aetiology of pneumonia, to define the burden of pneumococcal disease, and to monitor vaccine efficacy and effective-
ness. This article summarizes a meeting on the diagnosis, detection and serotyping of pneumococcal disease organized by PATH and
Fondation Me´rieux (18–20 October 2009, Fondation Me´rieux Conference Centre, Les Pensie`res, France). Workers and experts met to
discuss the gaps in the microbiology-based diagnosis of Streptococcus pneumoniae disease, with special emphasis on pneumonia. The
meeting was designed to evaluate the state of the art of pneumococcal diagnostics and serotyping methodologies, identify research and
development needs, and propose new guidelines to public health authorities to support the introduction of vaccines. Regarding detec-
tion, the main recommendations were to encourage chest X-rays and antigen detection in urine. Large-scale studies are needed to eval-
uate the diagnostic utility of test algorithms that associate chest X-rays, antigen detection in urine, S. pneumoniae quantitative PCR in
nasopharyngeal aspirates and sputum, and C-reactive protein or procalcitonin measurement in blood. Efforts should be focused on pro-
teomics to identify pneumococcus-specific antigens in urine or host markers in blood expressed during pneumonia. It was recom-
mended to develop S. pneumoniae typing capacities, to understand the epidemiology of pneumococcal disease, and to evaluate vaccine
effectiveness. Simple and effective approaches are encouraged, and new technologies based on beads, microarrays or deep sequencing
should be developed to determine, in a single test capsular serotype, resistance profile and genotype.
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Introduction
Pneumonia remains the leading cause of mortality resulting
from infectious disease worldwide. In 2008 alone, it killed
nearly 1.6 million children <5 years of age [9]. In Bangladesh,
for example, pneumonia is responsible for filling 32% of pae-
diatric hospital beds [56]. The term ‘pneumonia’ is often
used in reference to respiratory disease resulting from a
variety of infectious causes, but often carries an unspoken
aetiological assumption that the disease is probably bacterial
in origin and therefore requires antibiotic therapy.
Although it is true that Streptococcus pneumoniae is the
most common aetiological agent of pneumonia, Moraxella ca-
tarrhalis, Haemophilus influenzae, Mycoplasma pneumoniae,
Bordetella pertussis and other bacterial species also cause the
disease. It is also true that non-bacterial agents can be
responsible for causing pneumonia, including more than 20
viruses and several fungal agents. A number of parasites have
also been associated with pneumonia [21,78]. In addition,
recent data have shown associations between severe respira-
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tory disease in children and co-infection by two or more
viruses [65] or with synergistic interactions between bacte-
rial pathogens such as pneumococci and a number of respira-
tory pathogens such as influenza virus, respiratory syncytial
virus [44,45,52,81], and human metapneumovirus [48].
Tuberculosis can also be responsible for a significant propor-
tion of pneumonia diagnoses, and it too can act synergisti-
cally with pneumococcal infection [53]. For the purposes of
this review, we will use the term ‘pneumonia’ in reference
to the clinical disease, regardless of aetiology. We will use
the term ‘pneumococcal pneumonia’ when S. pneumoniae is
the specific aetiology.
The most common causes of severe pneumonia are lar-
gely vaccine-preventable. Vaccines against S. pneumoniae and
H. influenzae type b are available and being increasingly used
worldwide to provide protection. Following the introduction
of the seven-valent pneumococcal conjugate vaccine (PCV-7),
the Active Bacterial Core surveillance program, covering
9.3% of the US population, demonstrated a sustainable 76%
reduction among children <5 years of age in the incidence of
invasive pneumococcal disease (IPD), which includes pneu-
monia, bacteraemia, and meningitis [5], and the number of
pneumonia hospitalizations has dropped by about 40% in the
USA among children <2 years old [27]. However, vaccine
efficacy is probably lower in developing countries and for
clinical syndromes that are less often pneumococcal, e.g. in
South Africa, where a study on 39 836 children reported a
reduction in incidence of only 16%, with clinical pneumonia
as an outcome measure [46].
S. pneumoniae vaccine probe studies have shown that the
real burden of pneumococcal pneumonia is much higher than
originally suspected [46]. Studies have also demonstrated
that vaccination reduces the rates of hospitalization of
patients with culture-positive tuberculosis, suggesting that
pneumococcal co-infections may also play a role in tubercu-
losis. Vaccination against pneumococcus has been shown to
prevent hospitalization for influenza [45], and is also likely to
prevent co-infections with Pneumococcus. Prevention of viral
infections may also contribute to the reduction in pneumonia
incidence, although this has not been demonstrated, and no
vaccines against major respiratory viruses apart from influ-
enza virus are available.
Improved methods for diagnosing pneumonia are needed
to better inform health policy-makers. Traditional diagnosis
of pneumonia relies on clinical examination, including chest
X-rays (CXRs), and physiological and host response examina-
tions. Although CXR is considered to be the reference stan-
dard for pneumonia diagnosis today, CXR evaluation cannot
specifically determine pneumonia aetiology. Wider use of
and improvements in microbiological techniques are possible,
and warrant further exploration. In Bangladesh, for instance,
blood culture testing increased from 5% to 37%, increasing
the number of diagnosed pneumococcal cases (S. Saha,
unpublished data). However, vaccine probe studies have
shown that blood culture sensitivity should be improved,
because it fails to detect an aetiology in most pneumonia
cases. Antigen detection in urine has also come into more
frequent use in adults, while researchers explore other inno-
vative ways to detect S. pneumoniae.
Epidemiological surveys of IPD in the USA have shown
that cases remaining after vaccine introduction (23 cases per
100 000) are primarily attributable to non-PCV-7 serotypes
[61]. Serotype replacement potentially threatens to erode
the tremendous benefits of the pneumococcal conjugate vac-
cines, with reports in the literature indicating an increase or
change in non-vaccine-related pneumococcal serotypes in the
nasopharynx following vaccine introduction [30]. Under-
standing multiple serotype carriage in addition to disease is
therefore critical for predicting and monitoring conjugate
vaccine effectiveness, measuring changes in disease epidemi-
ology, and determining the impact of serotype replacement.
S. pneumoniae serotype 19A has emerged among carriage
and invasive cases in the USA, and seems to have reached a
plateau; however, the proportion of penicillin-resistant sero-
type 19A strains is increasing [5]. The role of other patho-
gens in replacement is still not clearly understood.
In 18–20 October 2009, 40 experts on pneumococcal dis-
ease diagnosis from research organizations, hospitals, the
vaccine and diagnostic industry and funding agencies met in
Les Pensie`res, France, to address the needs and the state of
the art of clinical diagnosis of pneumococcal disease, labora-
tory-based identification of S. pneumoniae identification, and
molecular epidemiology. New technologies and research
needs were extensively discussed. This article summarizes
the main points and recommendations discussed by the
speakers, and some recent developments in these fields.
Unmet Needs for Pneumonia Diagnosis,
Laboratory-based Surveillance, and
Epidemiological Surveys
The capacity to detect pneumococcal pneumonia is extraordi-
narily limited, in large part because of problems in obtaining an
optimal specimen for diagnosis. Blood cultures from pneumo-
coccal pneumonia cases are often negative, and respiratory
specimens such as sputum or nasopharyngeal samples can be
confounded by the presence of normal flora. Because a com-
prehensive aetiological evaluation of all pneumonia cases by
syndrome-based laboratory diagnosis would be too costly and
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technically challenging, researchers do not have a full under-
standing of the major burden of non-bacteraemic pneumococ-
cal disease. As a result, it is not known which tests are needed
to enable a real syndrome-based aetiological diagnosis of pneu-
monia. More accurate tests are needed to eliminate wasteful
and non-productive treatments and to limit the development
of antimicrobial resistance. Enabling earlier diagnosis is also
important for starting optimal therapy sooner, improving
treatment effectiveness, and reducing the spread of disease.
Simpler, easy-to-use tests may also increase access to and
expand the use of diagnostics.
Pneumococcal IPD surveillance has several important
objectives. Information on disease burden can build local
awareness of disease, enable evaluation of health impacts
resulting from interventions, and inform treatment priorities
and prevention strategies. Surveillance can also help in the
identification of high-risk groups, description of syndrome
distribution, identification of the predominant disease-causing
serotypes, and monitoring of antibiotic susceptibility patterns.
Additionally, it can provide valuable information to the vac-
cine researchers and policy-makers on disease burden, vac-
cine cost effectiveness, and vaccine development.
Unfortunately, hospital-based surveillance frequently
underestimates the burden of pneumococcal disease. Rates
of specimen collection from pneumonia patients are rela-
tively low, particularly in non-research settings. Specific
detection of S. pneumoniae classically relies on blood culture,
which is insensitive and most often not available at the point
of care; also, its results are typically not available until several
days after specimen collection, and it may be performed at
another institution. Also, current culture-based tests for
pneumococcal pneumonia require viable organisms, posing
challenges to specimen collection and handling. Another fac-
tor to consider is that hospital-based surveillance will miss
milder cases treated in the outpatient setting.
All available tests for pneumococcal detection and sero-
typing have limitations and variable performance in different
settings, leading to underestimation of pneumococcal pneu-
monia disease rates in comparison with illnesses with more
robust surveillance, such as meningitis.
Although S. pneumoniae is the major cause of pneumonia,
it is also important to consider surveillance of other bacte-
rial, viral and parasitic causes of pneumonia, including testing
methods that differentiate bacterial from non-bacterial infec-
tions and that detect all pathogens in a syndrome-based
approach. Ideally, tests should be able to detect all pneumo-
coccal diseases—pneumonia, meningitis, septicaemia, and
others—and, in addition, determine antimicrobial resistance
patterns and serotypes of strains causing disease. To achieve
this will probably require testing methods using pleural fluid,
blood, cerebrospinal fluid (CSF), nasopharyngeal swabs,
urine, and high-quality sputum samples. The ability to quanti-
tatively detect multiple serotypes within nasopharyngeal
specimens would be ideal for a better understanding of car-
riage and its relationship with pneumococcal disease. How-
ever, the positive predictive value of quantitative PCR for
diagnosing pneumococcal pneumonia using sputum and naso-
pharyngeal specimens is recognized to be low, especially in
children [84].
In general, ideal diagnostic tests should not necessarily rely
on the culture of viable organisms, must have high specificity
and sensitivity, and should not be affected by prior antibiotic
treatment. In addition, they should be inexpensive and easy
to use without extensive training. Finally, pneumococcal test-
ing methods should not jeopardize surveillance for antimicro-
bial resistance or other pathogens.
Laboratory-based Technologies for
Diagnosis and Surveillance
Identification techniques
The main recommendations of the expert group for the
diagnosis of pneumococcal pneumonia are detailed in
Table 1. Laboratory-based diagnosis of pneumonia currently
considers S. pneumoniae, largely because of the exclusion of
other potential aetiologies. Although PCR from nasopharyn-
geal specimens for multiplex detection of atypical bacteria,
viruses and parasites in a syndrome-based approach is prom-
ising, it is only slowly becoming part of hospital routines in
industrialized countries. In addition, the detection of S. pneu-
moniae in nasopharyngeal specimens is indicative of carriage,
but its use for the determination of pneumonia aetiology is
currently of little interest.
No true reference standard exists for the diagnosis of pneu-
mococcal pneumonia. Clinicians today typically use a combina-
tion of patient medical history, examinations, CXR and other
selected tests to diagnose pneumonia in their practices. To
determine pneumonia aetiology, they may also use blood cul-
ture, antigen detection in urine, C-reactive protein (CRP), and
procalcitonin (PCT). Serology is of little help in these acute
settings, as it requires serum from the convalescent phase, but
the advent of platforms for simultaneous determination of
multiple serotype-specific antibody responses may make these
assays more useful in study settings. A consensus regarding the
sensitivity of PCR from blood as compared with other diagnos-
tic methods seems promising, although large-scale confirma-
tion is still required. The use of PCR on nasopharyngeal
specimens and sputum appears, at this time, to be limited,
because of concerns that a sample may be positive with either
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carriage or disease. PCR also has high costs and the need for
sophisticated instruments, infrastructure requirements, and
technical skills among personnel.
Detection of S. pneumoniae in blood. Vaccine probe studies
have shown that blood culture methods for detecting
S. pneumoniae capture only approximately 10–20% of sus-
pected pneumococcal pneumonia cases, with the sensitivity
in infants being even lower [50]. Possible explanations for
these low rates of success could be the inherently low den-
sity of the organism in blood, prior antibiotic treatment, con-
tamination of blood samples and cultures, insufficient blood
volumes, incorrect ratios of blood to broth, delays in trans-
porting blood culture bottles to the laboratory, and delays in
performing subcultures of blood cultures.
One way of increasing the success of blood culture as a
method of detecting pneumococci is to build skills among
nurses and laboratory staff through training in blood culture
standard protocols, which include critical procedures for
hospitalized patients, outpatients, and emergency room
patients. Protocols are widely available in the literature, and
should be made more accessible, especially through e-learn-
ing. Currently, from a cost and practicality standpoint, PCR
or antigen-based assays may have the potential for assessing
‘beep-positive’ or chocolatized, culture-negative culture bot-
tles. In these cases, pneumococcal DNA or antigen concen-
trations are high, although pneumococci have reached the
stationary phase and subsequently lysed. In a study on 2739
patients, the use of the immunochromatographic antigen test
on chocolatized blood culture bottles led to the identifica-
tion of eight invasive pneumococcal cases in addition to the
1605 cases detected by blood culture alone [69].
Matrix-assisted laser desorption ionization time-of-flight
mass spectrometry (MALDI-TOF MS) is starting to be used
in clinical microbiology laboratories for routine bacterial
identification from colonies (for a review, see ref. [74]).
MALDI-TOF MS has also been used for diagnosis on positive
blood cultures [23,43,79]. This technology is promising, as it
reduces the cost and time to result of bacterial identification.
However, the performance of MALDI-TOF MS for Strepto-
coccus spp. is generally weak, and further studies are
required to improve differentiation between S. pneumoniae
and closely related viridins species such as Streptococcus mitis
[74].
In addition to the building of skills among medical and
microbiology personnel, the development of more sensitive
and specific assays is also needed. The use of S. pneumoniae
PCR in blood for the diagnosis of IPD, for example, is one
method whose true value has yet to be fully explored.
Although several reports have shown lytA (autolysin),
Spn9802 or pneumolysin gene (ply) PCR in serum to be less
sensitive than blood culture in adults [1,15,59], more recent
studies, using more sensitive quantitative assays, have shown
the opposite for lytA [4,36,64]. LytA PCR also been shown to
be more sensitive than detection of techoic acid (Binax-
NOW; Inverness Medical, Princeton, NJ, USA) in urine [61].
Ply PCR, in particular, is not specific and shows cross-reac-
tions with other streptococcal species. In addition, not only
is the gene target important, but exactly which segment of
this gene is targeted is apparently also important, owing to
allelic variation in the target gene between closely related
species.
Serotype-specific real-time PCR assays are also showing
promise for low-concentration DNA extracts prepared from
whole blood and other clinical specimens [4,54] (Carvalho,
Mda G. et al., unpublished data). Moreover, when positive, a
high bacterial DNA load has been associated with increased
mortality and higher risk of septic shock [14,61].
The properties of the antigen pneumococcal choline-bind-
ing protein A (PcpA) could be used to design and validate an
antigen assay in blood that could be specific for pneumococ-
cal pneumonia. PcpA is expressed only in the presence of a
low manganese concentration, which is the case in blood
(<0.1 lM Mn2+) as compared with nasopharyngeal specimens
(40 lM Mn2+) [34]. In addition, studies have shown that
TABLE 1. Recommendations for diagnostic test use and
development for pneumococcal pneumonia
Chest X-ray (CXR) remains the reference standard for diagnosis of pneumonia
syndrome, and should be used when available, especially for hospitalized patients.
Blood culture is insensitive but can provide a specific aetiological diagnosis
and should be used when available.
When blood culture is not available, Streptococcus pneumoniae teichoic acid
antigen detection in urine (Binax) may be an alternative, although its specificity
is low in children. The use of BINAX NOW also cleared by the Food and
Drug Administration for use with cerebrospinal fluid in the USA. Data
supporting the use of antigen detection have been also published for
presumptive Spn identification in bronchoalveolar lavage fluid, pleural fluid,
and blood culture.
Quantitation of DNA loads by using real-time PCR in nasopharyngeal specimens
is promising as a diagnostic method; however, the practical use of this
measurement for differentiation of invasive pneumococcal disease (IPD) from
carriage must be evaluated, as many children without pneumonia have high
bacterial densities in nasopharyngeal specimens.
The detection of S. pneumoniae in blood by PCR needs to be further explored.
A high bacteraemia load detected by quantitative PCR may be predictive of
pneumonia severity.
The measurement of C-reactive protein (CRP) or procalcitonin (PCT) in serum
may be a useful adjunct to improve the specificity of CXR, antigen detection
in urine, and S. pneumoniae PCR in nasopharyngeal specimens.
Large-scale studies are needed to evaluate or confirm the diagnostic utility of
test algorithms that associate CXR, antigen or DNA detection in urine,
S. pneumoniae or pneumonia PCR in nasopharyngeal specimens with CRP or
PCT.
Multiplex syndrome-based diagnoses of respiratory pathogens would enable
accurate aetiological diagnosis of pneumonia besides IPD.
Research efforts should focus on proteomics to identify new, more specific
antigens in urine or host markers in blood. They should also explore using
transcriptomics to identify new pathogens or host genes expressed differently
in blood during IPD.
Development should focus on ASSURED (affordable, sensitive, specific,
user-friendly, rapid, equipment-free, delivered to those who need it) tests
for S. pneumoniae antigen in urine, host markers in blood, and S. pneumoniae and
pneumonia syndrome-based assays in nasopharyngeal specimens.
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PcpA is expressed in the lungs, but not in the nasopharynx
[26], which makes this target promising for distinguishing
pneumococci causing carriage from those causing pneumonia.
Antigen detection in urine. Extensive efforts to validate the Bi-
naxNOW assay have shown the assay to be more sensitive
than blood culture, and to be able to identify more cases of
pneumococcal pneumonia than traditional methods in both
inpatient and outpatient settings [2,17,25,28,31,39,80]. It is
easy to use and non-invasive, but the assay lacks specificity in
children, because it can give positive results in healthy chil-
dren with carriage of pneumococci and of other closely
related Streptococcus species. Increasing the cut-off at which
the assay result is determined to be positive could improve
the specificity, but doing so would require extensive valida-
tion to determine the impact on sensitivity. Although there
is an enormous literature on the use of BinaxNOW in urine
specimens, little is known about its use in serum.
Assays based on other antigens, including proteins (PpmA,
Ply, or PcpA) or polysaccharides that may also allow typing,
are less sensitive or specific than BinaxNOW, but this
approach warrants further research to search for better anti-
gens and methodologies. Proteome profiling in urine could
help to identify new antigens that could be useful in the
development of new diagnostic assays.
Serotype-specific antigen detection in urine might be a
promising approach to detect serotype-specific pneumonia in
adults [75], but may also be confounded by carriage in chil-
dren. Plasmodium and mycobacterial DNA can be detected in
urine and inform diagnoses, possibly making it worthwhile to
look for S. pneumoniae DNA in urine and to explore the sensi-
tivity and specificity of a urine PCR-based assay for the detec-
tion of invasive pneumococcal disease, including pneumonia.
S. pneumoniae PCR in nasopharyngeal specimens or spu-
tum. PCR in nasopharyngeal specimens and sputum is more
sensitive than culture, especially in patients receiving antibiot-
ics [1,33,35]. It must be mentioned here that the classic high
predictive value of the Gram stain and pneumococcal culture
from a high-quality sputum specimen should be fully appreci-
ated in the modern era [55].
A broth enrichment step of 4–6 h in conjunction with
conventional culture and PCR techniques increased the sen-
sitivity of pneumococcal detection in nasopharyngeal speci-
mens by 15–20% in carriage prevalence studies [16]. Broth
enrichment in combination with conventional PCR frequently
allows the detection of multiple serotypes, which is rarely
achieved with the current WHO-recommended culture-
based approach [57]. However, culture-based amplification
(broth enrichment) of nasopharyngeal specimens would not
be predictive of the relative concentrations of the different
serotypes originally present. For this purpose, a quantitative
PCR approach without broth enrichment might be most
applicable; however, this would be suboptimal for the detec-
tion of low-density serotypes [16].
Ply quantitative real-time PCR (qRT-PCR) in sputum
appears to be promising: the sensitivity and specificity as
compared with a composite reference standard comprising
Gram staining of sputum samples and sputum/blood cultures
were as high as 90% and 80%, respectively, using a cut-off
value of 3.7 · 104 genomic equivalents of S. pneumoniae per
millilitre of sputum [84]. However, obtaining good-quality
sputum from infants can be difficult, unless it is induced spu-
tum. Spn9802 qRT-PCR in nasopharyngeal specimens also
performed well with a cut-off value of 104 genomic equiva-
lents of S. pneumoniae per millilitre of nasopharyngeal speci-
men [1]. Large clinical studies are required to validate the
use of pneumococcal qRT-PCR on nasopharyngeal specimens
in children with suspected pneumonia in developing coun-
tries.
The bacterial load in nasopharyngeal specimens by quanti-
tative PCR may be predictive of pneumonia. A recently pub-
lished study on 550 hospitalized children in Vietnam showed
that the median nasopharyngeal bacterial load of S. pneumo-
niae was substantially higher in children with CXR-confirmed
pneumonia than in healthy controls or children with other
lower respiratory tract infections (LRTIs) [81]. This was also
true for H. influenzae and M. catarrhalis. However, the diag-
nostic usefulness of bacterial load in nasopharyngeal speci-
mens is still unclear, as many children without pneumonia
carry a high density and the quantities may be serotype-spe-
cific.
Experimental approaches to the use of nasopharyngeal
specimens for diagnosing pneumonia may also rest on the
idea that there may be differences in patterns of gene
expression in nasopharyngeal pneumococci between carriage
and pneumonia. Many virulence genes are differentially
expressed in bacteria isolated from blood or CSF as com-
pared with nasal secretions in mice [50]. Different quantities
of capsular polysaccharide are observed between virulent
and avirulent pneumococcal phenotypes associated with IPD
and carriage, respectively [37]. Host immune protein gene
expression is also different in niches linked to IPD. A collab-
orative transcriptomic research project should be encour-
aged to identify genes and proteins that are differentially
expressed in IPD and carriage.
However, to be widely used in developing countries, PCR
techniques need to be simpler and more robust. The Gen-
eXpert system of Cepheid (Sunnyvale, CA, USA; http://
www.cepheid.com/) or the Film Array system from Idaho
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Technology (Salt Lake City, UT, USA; http://www.idahotech.
com) integrate reagents in a sealed device that prevents con-
tamination of the whole process, from sample preparation to
multiplex detection of PCR products, reducing infrastructure
and competence needs. The Enigma platform for integrated
real-time PCR (Enigma Diagnostics, Salisbury, UK; http://
www.enigmadiagnostics.com) is fully portable, and uses self-
contained reagents that are stable at ambient temperature.
Nevertheless, instrument platforms that require limited
maintenance are still to be developed for field applications.
In addition, costs per test may remain an obstacle for many
years.
Serology. The detection by immunoassay of pneumolysin, C-
polysaccharide or mixed capsular polysaccharide antibodies
trapped in immune complexes has been evaluated as a diag-
nostic tool for pneumococcal pneumonia in Kenyan adults,
but its sensitivity and specificity were insufficient [71]. An
immunoassay that detects IgG against pneumococcal surface
adhesin A, as compared with blood culture, increased the
sensitivity for diagnosis of pneumococcal pneumonia in adults
from 23% to 56%, with good specificity [72]. However, the
sensitivity of this assay for detecting pneumonia in children is
not sufficient [73]. Although serology is not affected by prior
antibiotic use, its use is limited to epidemiological studies,
and it has drawbacks, such as the potential for detection of
antibodies induced by carriage and the difficulty in obtaining
acute and convalescent sera from the patient.
Assays of antibody functionality (opsonophagocytic activ-
ities), such as those that detect IgM or low-avidity IgG, are
used to diagnose acute infections caused by, for example,
cytomegalovirus, rubella virus, dengue virus, or Toxoplasma
gondii. This approach may be worth exploring for IPD diag-
nosis, although it may be necessary to use conditions that
disrupt immune complexes.
Host markers. S. pneumoniae vaccine probe studies have
shown that serum CRP concentrations higher than 40 ng/mL
and PCT concentrations higher than 5 ng/mL add specificity
to the CXR diagnosis of pneumococcal pneumonia [47,49].
Studies involving limited numbers of children hospitalized
with LTRIs have demonstrated that elevated PCT is corre-
lated with positive PCR, serology and CXR confirmation, but
not with positive BinaxNOW test results in urine. PCT has a
sensitivity of 86% and a specificity of 88% for the differentia-
tion of bacterial and viral LRTIs. The specificity of CRP and
the sensitivity of interleukin-6 are both lower than those of
PCT. Studies in large cohorts of children in developing coun-
tries should be encouraged to further document the clinical
utility of PCT in pneumonia diagnosis.
A recent study on 835 children from Mozambique with
clinically severe pneumonia, 87 with viral pneumonia and 89
with invasive bacterial pneumonia, showed that, in the
absence of infection with malarial parasites, levels of PCT
and CRP were lower in the viral group than in the invasive
bacterial group (PCT, median = 0.21 ng/mL vs. 8.31 ng/mL,
p <0.001; CRP, 18.3 mg/L vs. 185.35 mg/L, p <0.001). How-
ever, in the presence of malarial parasites, the distribution
between clinical groups overlapped, and neither of the two
markers could predict mortality [19].
Syndrome-based pneumonia aetiology. Despite an obvious need
to establish more comprehensive ways of diagnosing pneu-
monia aetiology, particularly for the improvement of patient
management, viral and bacterial pathogen multi-detection
methods are unlikely to be widely available in the near future
in developing countries. Developed countries, however, are
gradually starting to introduce a complete diagnostic
approach in hospitals for the most severe pneumonia cases,
but further studies are needed to determine their utility and
cost-effectiveness.
Studies to broadly evaluate pneumonia aetiologies should
be introduced into surveillance schemes. Some commercial
laboratory tests, all based on PCR, are emerging for the
detection of some of the major causes of pneumonia. These
tests are generally multi-detection assays that identify mostly
viruses and atypical bacteria, although some of them also
include S. pneumoniae and other respiratory bacteria. The
formats for these tests include the following: multiplex real-
time PCR (Fast-Track Diagnostics, Luxembourg); PCR fol-
lowed by detection with beads (xMAP; Luminex, Austin, TX,
USA); mass spectrometry (MassTag); size fractionation on a
capillary electrophoresis system (RespiFinder; Life Technolo-
gies, Carlsbad, CA, USA); or microarrays such as TaqMan
Low Density Array (Life Technologies) or INFINITI (AutoG-
enomics, Carlsbad, CA, USA).
Adaptation of these platforms to the needs of clinics at
district or local levels has yet to occur, even in hospitals
located in major cities. Platform technologies, such as Cep-
heid’s GeneXpert, reduce dependence on highly skilled tech-
nologists, but still require significant maintenance and involve
high costs per test. For wide use in developing countries,
these multi-detection assays must satisfy the same criteria as
assays for S. pneumoniae detection described previously.
Typing techniques
The main recommendations of the expert group for S. pneu-
moniae typing are detailed in Table 2.
The serotyping reference standard is microbiological cul-
ture followed by the Quellung reaction, which is labour-
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intensive and used by only a few laboratories worldwide.
Descriptions of attempts to simplify traditional antibody-
based techniques such as the latex agglutination and/or
sweep methods are available in the scientific literature. Latex
agglutination has proved to be an invaluable tool for serotyp-
ing of pneumococci [76]. Other options for serotyping
include alternative techniques using molecular approaches,
which may also have the potential to provide further infor-
mation such as the multilocus sequence type or antimicrobial
resistance patterns. In the text below, we review some of
the serotyping technologies, with a particular focus on
recently developed methods, including possible improve-
ments, and an overview of innovative approaches under
exploration to fulfil unmet needs.
Antibody and molecular-based serotyping. The current reference
standard for serotyping of pneumococci is culture followed
by a capsular reaction test (Quellung reaction or Neufeld
test). Only a few laboratories in the world have a compre-
hensive, self-maintained set of typing antisera corresponding
to the currently known 92 capsular serotypes. Accurate use
of this methodology is particularly challenging and requires
experienced laboratory technicians, and is therefore not eas-
ily transferable to laboratories in developing countries. Other
serotyping methods include latex agglutination assays, which
use beads coated with antisera to type to the serotype or
group level [29] and, in some cases, to the serotype level
(Pneumotest-latex) [75]. Although much faster than the
Quellung reaction, this technique is often not as exacting and
is also labour-intensive. Home-made latex reagents are also
widely used; however, caution is needed in conducting
proper quality control testing.
Descriptions exist in the scientific literature for alternative
antibody-based technologies such as ELISA (seven serotypes)
[77], colony blot [10], dot blot assays using intact pneumo-
cocci (15 serotypes) [22], or immunoblot [11]. These assays
have global performance characteristics similar to those of
the Quellung reaction, but they have not been developed to
test a large number of serotypes. Multibead inhibition immu-
noassays using a flow cytometer, Luminex or BioRad Bio-
plex platforms allow for high multiplexing and throughput,
and have a high concordance with the Quellung assay
[24,75,85]. Evaluation of the usefulness of the Bio-plex assay
as a tool for identifying pneumococcal serotypes directly
from CSF specimens or isolates from children with meningi-
tis in an African setting will take place in the near future
(MRC, Fajara, The Gambia). Gas chromatography/mass selec-
tive detection for the analysis of S. pneumoniae capsular poly-
saccharides [38], nuclear magnetic resonance spectroscopy
[83] and Fourier transform infrared spectroscopy [70] may
also be used for S. pneumoniae serotyping.
Serotyping by multiplex PCR has also been described by a
number of researchers [8,58,66,67]. In such cases, several
panels of primers are applied to determine the serogroup or
type. For the CDC, these protocols are regularly updated at
the US Centers for Disease Control and Prevention website.
The current CDC assay efficiently resolves 40 different sero-
types or serogroups (http://www.cdc.gov/ncidod/biotech/
strep/pcr.htm). Usually, a first set of primers covers the
most prevalent serotypes, and subsequent sets cover less
common serotypes. For the typing to be most efficient, each
set may require adaptation to local serotype prevalence or
the specimen set under evaluation, particularly because of
geographical differences, different serotypes in carriage and
pneumonia cases, and culture-positive and culture-negative
CSF from patients with meningitis. For example, in a multi-
plex strategy developed in Bangladesh, the first primer set
covered 31% of pneumonia/sepsis isolates (48% of meningitis
isolates), but the use of seven sets covered 99% of all inva-
sive isolates [68]. In this scenario, the first set of the Ban-
gladeshi algorithm covers only 18% of African isolates and
9% of US isolates. Surveillance in Bangladesh has detected
only 45 serotypes causing invasive disease. Serotypes 13, 9L,
17F, 17A, 28A, 35C and 36 do not appear as invasive strains,
whereas 12 serotypes make up 80% of isolates. The database
of capsular gene sequences for all serotypes, available at
http://www.ncbi.nlm.nih.gov/Genbank, has proven to be a
valuable resource for assay development [6].
Multiplex PCR also improves serotyping in carriage stud-
ies. When applied on colonies obtained through culture from
nasopharyngeal specimens, PCR is able to identify the puta-
tive serotype in more nasopharyngeal specimens than the
Quellung reaction. In addition, PCR allows the detection of
multiple serotypes from mixed cultures or non-viable speci-
mens, although the entire set of reactions should be applied
TABLE 2. Recommendations for typing assays used for
pneumococcal surveillance
Bead assays can automate antibody-based and DNA-based serotyping assays
and replace the labour-intensive Quellung technique, which is the present
reference standard for serotyping.
Sequential multiplex PCR tests are less labour-intensive and expensive than
the Quellung reaction, making implementation more feasible for public health
laboratories in developing countries. However, until we have a full resolution
of the specific DNA signatures essential for expression of each individual
serotype, some reference laboratories should continue the use of Quellung
tests for quality control.
Real-time multiplex PCR serotyping should be developed and evaluated for
diagnostic purposes. For routine serotyping, newly developed nanofluidic
platforms should prove practical and inexpensive.
New analytical techniques such as mass spectrometry, microarrays, microfluidics
or deep sequencing may allow complete genotyping of strains from various
specimens and the determination of serotype, resistance profile, antigen
profiles and multilocus sequence types in a single test. Detailed clonal dissection
and tracking of recombinant events in real time is feasible with current genomic
sequencing technology.
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to avoid bias in serotype detection. Prior identification of
pneumococci in specimens with a real-time assay (lytA-based)
allows the targeting of only positive specimens for the more
cumbersome PCR-based serotyping assays [16].
Sequential multiplexed real-time PCR assays are also cur-
rently being developed to identify 21 capsular serotypes [4],
22 serotypes (B. Beall, unpublished data), or 29 serotypes
(G. Vernet, G. Baccala, J.-N. Telles, unpublished data). The
last of these, based on 4-plexes, has been shown in a preli-
minary evaluation to be able to identify a serotype in more
than 90% of 520 nasopharyngeal or blood specimens from
South Africa, Brazil, and Paraguay. Real-time multiplex PCR
has been shown to be more sensitive than conventional
sequential multiplexed PCR, as demonstrated on a panel of
67 nasopharyngeal specimens and sterile fluids [4].
Although real-time PCR serotyping assays are undoubtedly
more sensitive, a major attractive feature of the conventional
sequential multiplex PCR assay is that it allows laboratories
with the modest capability for conventional PCR to perform
quite comprehensive capsular serotype surveillance of pneu-
mococcal isolates, and to identify pneumococci and sero-
types within certain clinical specimens such as CSF, pleural
fluid, and nasopharyngeal specimens. In general, CDC Strepto-
coccus laboratory researchers have found that the conven-
tional sequential multiplexed PCR assay is reliable for
identifying serotypes in DNA extracts that display Ct values
£30 in a lytA real-time PCR assay, and that 1–3-plex real-time
PCR assays are reliable for Ct values of 30–35. They consider
lytA assay Ct values of >35–40 to be subjective and Ct values
of >40 to be negative.
For pneumococcal strains causing disease, discrepancies
between antibody and sequential PCR approaches employing
serotype-specific gene sequences are rare. In a documented
example, however, a strain identified as serotype 19F with
the Quelling test yielded a false-positive serotype 19A result
when tested with sequential multiplex PCR, because the
strain’s cps locus target had more similarities with known
serotype 19A sequences [62]. Problems also arise in differ-
entiating certain serotypes. For example, only one base pair
dictates the structural difference between serotype 6A and
6B capsular polysaccharides; however, a reliable PCR assay
has recently been developed to resolve these serotypes
[32]. Also complicating serogroup 6 resolution into its com-
posite serotypes is the recent discovery of two additional
serotypes created by the recombinational replacement of
the wciN-alpha gene within serotypes 6A and 6B with the
unrelated wciN-beta, resulting in serotypes 6C and 6D,
respectively. To ensure against error, at least some refer-
ence laboratories should continue using the Quellung reac-
tion in parallel with sequential PCR-based serotype
determination until biologically based sequence signatures
can be identified for each serotype. Discrepancies between
molecular methods and Quellung results are more common.
The non-encapsulated phenotype is not uncommon among
carriage isolates, many of which apparently contain non-func-
tional serotype-specific gene sequences. Alternative molecu-
lar technologies have been described for S. pneumoniae
typing, including multiplex PCR-based reverse line-blot
hybridization [13] or PCR and capillary electrophoresis [42].
Restriction fragment length polymorphism analysis and ter-
minal restriction fragment length polymorphism analysis for
mixed-serotype samples have also been described; however,
they use a non-cps target to predict serotype [30]. Similarly,
some techniques are based on cps polymorphisms, but
employ genes that are functionally interchangeable between
different serotypes. To achieve the maximum resolution,
another strategy is to combine a multibead assay, in which
two antibody panels are sequentially used to cover the sero-
types of the 13-valent vaccine, and then the 23-valent vac-
cine (and six cross-reactive serotypes), with three primer
panels that achieve complete coverage of this limited num-
ber of serotypes. This assay is currently under validation (M.
Nahm, unpublished data).
Another technology for S. pneumoniae serotyping includes
microarray analysis. Bentley et al. [6] have designed a micro-
array (Agilent Technology) to determine S. pneumoniae
serotypes in nasopharyngeal specimens on the basis of sero-
type-specific oligonucleotides within the cps locus. The array
can potentially be used directly on nasopharyngeal speci-
mens, without culture and DNA amplification. It can detect
multiple serotypes and determine their relative abundance. It
can also identify novel serotypes (re-assortants) and help to
characterize non-typeable S. pneumoniae strains. After initial
validation on 90 isolates from the Serum Staten Institute,
testing of the array took place using 100 nasopharyngeal
specimens from The Gambia. DNA was extracted after
overnight growth, labelled, and hybridized on the micro-
array. The microarray identified a serotype in four additional
nasopharyngeal specimens as compared with culture-depen-
dent Quellung testing, and the presence of multiple
serotypes in 11 additional specimens (M. Antonio, unpub-
lished data).
Electrospray ionization mass spectrometry can discrimi-
nate between PCR products with very similar sequences
through base composition analysis, derived from determina-
tion of the mass/charge ratio of each DNA strand and com-
parison with a known library of PCR fragments obtained
with the given primer set [20]. Forty primer sets (32 amplify-
ing cps locus sequences and eight amplifying multilocus
sequence typing (MLST) loci) are used in a 8-plex assay on a
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96-well format. This technology was shown to resolve 43 dif-
ferent serotypes within a very highly diverse sample of 229
strains (B. Beall and R. Sampath, unpublished data). Of the
197 strains expressing serotypes included in the assay, only
two discrepancies (owing to amplification failure) were
observed. All 32 strains expressing one of 22 rare serotypes
not included in the assay yielded the expected negative
results. The MLST-based genotyping component was also
highly concordant for strains with genotypes highly related
to those included within the T5000 genotyping database. This
T5000 kit now has proven potential for characterization of
isolates, but needs to be validated on clinical specimens and
assessed for its capacity to detect multiple serotypes in car-
riage specimens. Overall, the performance of these technolo-
gies is promising, and will allow for higher throughput at
lower cost, as they are less labour-intensive and require
fewer skills. However, despite this promise, to be applicable
in developing countries these approaches should be further
standardized and validated, including the use of more auto-
mation. These techniques could ultimately be independent of
isolates and work directly on pleural fluid, whole blood,
blood culture bottles, CSF, or nasopharyngeal specimens [3].
Whereas conventional PCR approaches generally work well
for deducing serotypes from lytA-positive CSF specimens,
pneumococcal DNA concentrations are generally lower in
extracts prepared from whole blood, so more sensitive
DNA-based assays such as real-time PCR are more applica-
ble [4].
MALDI-TOF MS may prove valuable for pneumococcal
serotyping, and deserves further study. By use of the
MALDI BioTyper and its associated software for automated
data analysis (Bruker Daltonics, Billerica, MA, USA), it has
been possible to classify 109 of 110 Streptococcus agalactiae
strains at the serotype level [41]. Williamson et al. [82]
have been able to differentiate, at the genus, species and,
to a certain extent, strain level, bacterial isolates of
S. pneumoniae—including 13 non-typeable strains, seven vac-
cine strains, R6 and TIGR4, as well as four clinical iso-
lates—and 18 isolates of other Streptococcus spp. or of
other genera.
A recent initiative, the PneuCarriage project, coordinated
by C. Satzke (Murdoch Childrens Research Institute, Austra-
lia), will compare approximately 15 different antibody-based
and molecular-based methods for detecting multiple sero-
types within carriage specimens, using both laboratory-pre-
pared (spiked) and field swabs from children in developing
countries. The sensitivity and specificity of these methods in
detecting multiple serotype carriage will be determined, in
comparison with each other and also with traditional sero-
typing methods.
Antibody response to vaccine serotypes. The direct comparison
of antibody responses to the serotypes used for different vac-
cines is important for the evaluation of their efficiency. The
most common format for antibody testing is ELISA [18,40].
Commercial assays also exist, such as the Luminex Pneumo-
coccal Immunity Panel (xMAP Pneumo14), which enables the
quantitative assessment of IgG against 14 serotypes following
the administration of a pneumococcal vaccine [7,60]. An
evaluation of a panel of 80 sera showed IgG concentration
values obtained with this US Food and Drug Administration-
approved and European conformity-marked product to
be well correlated with those assigned to the 89SF standard
serum [63]. A new version of the product is currently
under development to measure antibodies for all PnPV23
serotypes.
An instrument platform that uses electroluminescence
chemistry, developed by Merck, has also been used for a
multiplex antibody assay for eight serotypes [51].
Comprehensive molecular typing techniques. The objective of
the MLST and Pneumococcal Molecular Epidemiology Net-
work (PMEN) databases (http://www.sph.emory.edu/PMEN
and http://pneumoniae.mlst.net/) is to better understand the
molecular epidemiology of S. pneumoniae at a regional and
global level. The PMEN specifically aims to expand its Global
Strain Bank with invasive and non-invasive strains from chil-
dren in developing countries, using genotyping, susceptibility
testing, and serotyping for characterization. Information on
the Global Strain Bank is available at http://www.cdc.gov/
ncidod/biotech/strep/global_pneumo_strain_bank.htm for com-
mercial and academic vaccine researchers.
Comprehensive and integrated assays covering all of these
needs in a single test would greatly improve strain character-
ization capacity. The introduction of genotypic techniques
has improved the capacities of laboratories to detect and
monitor the emergence and spread of clones that are resis-
tant to antibiotics. The combination of genotyping and sero-
typing techniques allows insights into the origin and
emergence of serotype switch and multiresistant strains.
Today, understanding the molecular epidemiology of
S. pneumoniae largely relies upon pulsed-field gel electropho-
resis and MLST. MLST has defined nearly 6000 different
sequence types on the basis of the combination of seven
housekeeping gene sequences. This technique has been useful
to demonstrate the emergence of specific clones; for exam-
ple, the post-conjugate vaccine emergence of a serotype 19A
capsular switch variant produced through an event involving
a common serotype 4 genetic recipient and a prevalent sero-
type 19A capsular locus donor [12]. The development of
new analytical technologies makes possible the simultaneous
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detection of multiple genotypic characteristics that are useful
for serotyping, resistance detection, genotyping, and evolu-
tionary analysis of strains.
Added to the microarray designed by Hinds et al. (see
above) are probes to identify other pathogens, such as H. in-
fluenzae and Clostridium difficile, that co-colonize the naso-
pharynx and to detect six antibiotic resistance genes. Finally,
the array has also been designed to study S. pneumoniae gene
expression.
Deep sequencing by technologies such as Solexa (Illu-
mina), 454 or AB SOLiD allows a massive increase in
sequence output as compared with older methods. For
example, Solexa generates 30 000 Mbp per run, an amount
approximately 15 000 times the genome size of S. pneumo-
niae. Even if 96 samples are sequenced in a single run, cov-
erage is still 166 times the genome size. This capacity
enables identification and comparisons of all known pneumo-
coccal genetic determinants, including those that encode
serotype, known virulence factors, and protein antigens,
multilocus sequence type, and antimicrobial resistance phe-
notypes. Costs of approximately US$100 per bacterial gen-
ome may currently be possible through higher sample
multiplexing.
Conclusion and Recommendations
Pneumonia is still killing millions of people each year, despite
it being a largely vaccine-preventable disease. Patient man-
agement, surveillance and vaccine effectiveness evaluations
require significant improvements in laboratory tools for
optimal identification and characterization of the major
respiratory pathogens. There is a strong need to support
research initiatives, from basic science to clinical validation.
Proteomic and genomic technologies must be used to iden-
tify new markers for diagnosis (e.g. markers of infection in
urine, and markers of host response to infection). New
technologies for specimen processing, marker detection and
typing (mass spectrometry, bead-based assays, microarrays,
and sequencing) could facilitate the implementation of diag-
nostics in laboratories and ultimately in the fields, for patient
management and pathogen surveillance. Existing assays must
be carefully evaluated in clinical settings to establish their
utility for disease diagnosis. In particular, the use of a combi-
nation of assays in parallel must be carefully evaluated,
including cost-effectiveness aspects. Collaborative projects
must be encouraged, between country infectious disease
surveillance centres, research centres (academic and com-
mercial–technological), and clinicians in the countries most
affected by the diseases.
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